Original news and analysis on international IP policy
The White House today announced measures that it said will advance its battle against "patent trolls", and urged Congress to pass patent reform legislation toward the effort. And the United States Patent and Trademark Office (USPTO) issued a statement on its work in support of the executive actions.
Nazeem Mohamed is chief executive officer of Kampala Pharmaceutical Industries (KPI), a Ugandan generic manufacturer. Local manufacture of medicines is described by many, including the World Health Organization, as one of the tools that will increase access to medicines. Mohamed is former vice-president of strategic product development at Novo Nordisk, based in Belgium. He also worked for several leading multinational companies such as Pfizer and GlaxoSmithKline before his appointment as CEO of KPI.
With Intellectual Property Watch, Mohamed discussed KPI, the challenges of local drug production, the burden of non-communicable diseases, the issue of substandard medicines, rules engineered in the West which can hinder affordability and access in a least-developed country, unfair competition, and unmet skills building needs.
After three rounds of negotiations for the Transatlantic Trade and Investment Partnership (TTIP), European Union Trade Commissioner Karel de Gucht this week welcomed the progress so far. But negotiators have to “step up a gear,” de Gucht said after a two-day stocktaking meeting with the United States Trade Representative Michael Froman in Washington, DC on 18 February. Meanwhile, USTR announced new steps to raise public participation in trade negotiations.
The much-debated Intellectual Property Laws Amendment Bill in South Africa, aimed at boosting protection for traditional knowledge, was signed by President Jacob Zuma without much fanfare and promotion. What happens now?
A recent report predicts the loss of at least $100 billion per year in intellectual property globally by 2018 as a result of 3D printing.
The European Parliament (EP) is scheduled to vote on 24 February on the draft Single Telecoms Package Regulation drafted by the Industry, Research and Energy Committee - on the future of neutral internet.
Over the last couple of years, news of pharmaceutical patents and India’s attempts to protect and manage its market has caught the attention of intellectual property observers everywhere and the pharmaceutical industry in particular.
On 1 November 2013, the South African Department of Trade and Industry published the draft "Promotion and Protection of Investment Bill" for comments. And two lawyers caution that if not careful, it could come in conflict with the country's international intellectual property obligations.
A coalition of large and small companies and organisation - including the leading trade associations for the US pharmaceutical and biotechnology industries - has asked the US Congress to use caution in rewriting patent laws so as not to cause unintended harm to their ability to innovate.
Over the revelations of mass surveillance of internet users and government officials, the topic of internet governance has risen to the mainstream political agenda. And a Communication on “Europe's role in shaping the future of Internet Governance” passed by the European Commission today would put “Europe in the center of the debate,” EC Vice President Neelie Kroes said in a press conference in Brussels.
The Office of the United States Trade Representative today published its annual list of online and physical marketplaces worldwide that are most engaged in sales and trafficking of counterfeit and pirated goods.
Dear Subscribers,
CPhI's 3rd Annual Pharma IPR 2014 conference to take place from 26-28 February, 2014 in Mumbai, India will have techno-legal experts from over 10+ regions speaking on the recent case studies on global Pharma and Biopharma patent laws.
Among them, Jeffery Alan Hovden, Partner, Robins, Kaplan, Miller & Ciresi LLP from US will be speaking on critical developments in US pharma patent law in the year 2013 which have affected pharma and biopharma industry. He will also share best strategies on how Indian generic-drug and biologics enterprises need to go forward with their US-related projects.
Some of the critical concerns he is planning to address include:
You can view his insights on "US Patent Law in 2013: Winds of Change" by clicking here.
To optimise interactions with the audience, he and other global techno-legal experts would also be available in query handling sessions as well as one-on-one meetings, to discuss your concerns related to the US patent system. Click here to go through the detailed programme agenda.
You can read more about the conference speakers here.
To be a part of this exclusive event, please contact the organisers at +91 (22) 6172 7001 / conferences-india@ubm.com, or register online and take advantage of the special offers for you as you are our subscribers.
P.S. You may find one of his earlier presentations on “From Small to Big: Some useful points in the coming shift from customary drugs to biologics” interesting - View the presentation here